Hybrid ‘clusterbombs’ as multifunctional nanoplatforms potentiate brain tumor immunotherapy

Abstract

A hybrid ‘clusterbomb’ as a multifunctional nanoplatform (MPSDP-ZnO/Ag) was developed for the combined immunotherapy of intracranial tumors. MPSDP-ZnO/Ag possessed high antigen loading and well-defined hybrid nanostructures, and could trigger the cluster to ‘bomb’ in response to antigen-presenting cells for simultaneous antigen and adjuvant release. The in vitro and in vivo results confirmed significant antigen accumulation and enhanced cellular and humoral immunity. More importantly, our nanovaccines obviously prolonged the survival time of tumor-bearing mice without systemic toxicity.